Home » Stocks » XLRN

Acceleron Pharma, Inc. (XLRN)

Stock Price: $116.50 USD -1.68 (-1.42%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 7.05B
Revenue (ttm) 112.94M
Net Income (ttm) -178.56M
Shares Out 60.58M
EPS (ttm) -3.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $116.50
Previous Close $118.18
Change ($) -1.68
Change (%) -1.42%
Day's Open 117.72
Day's Range 115.03 - 117.63
Day's Volume 239,129
52-Week Range 85.58 - 146.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Acceleron (XLRN) delivered earnings and revenue surprises of 7.23% and -9.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...

4 days ago - Business Wire

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2...

2 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics t...

1 month ago - Business Wire

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Acceleron (XLRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 month ago - Zacks Investment Research

Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.

2 months ago - Zacks Investment Research

Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 115.91% year over year to ($0.95), which misse...

2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics t...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...

2 months ago - Business Wire

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth qu...

2 months ago - Business Wire

Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to treat anemia...

Other stocks mentioned: BMY
2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron's President and Chief Executive Officer, will present a corporate overview during the 3...

4 months ago - Business Wire

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: BIIB, BIO, CVS, HZNP, MRNA, PODD, QDEL ...
4 months ago - Investopedia

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Other stocks mentioned: EDIT, FATE, FOLD, RARE
4 months ago - Zacks Investment Research

The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popula...

Other stocks mentioned: BCRX, HALO, QDEL, TDOC
4 months ago - Zacks Investment Research

Acceleron's (XLRN) investigational therapy sotatercept receives an Orphan designation in Europe for the treatment of patients with pulmonary arterial hypertension. Shares up.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics t...

4 months ago - Business Wire

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics t...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to t...

6 months ago - Business Wire

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript

6 months ago - Seeking Alpha

Acceleron (XLRN) delivered earnings and revenue surprises of -20.00% and -17.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...

6 months ago - Business Wire

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...

6 months ago - Insider Monkey

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quar...

6 months ago - Business Wire

Acceleron Pharma Plan For Sotatercept Adds To Buy Conviction

7 months ago - Seeking Alpha

MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL® (luspatercept) for the t...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

7 months ago - Business Wire

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

The Reblozyl launch by partner Bristol-Myers Squibb is going well.

8 months ago - Seeking Alpha

It's not uncommon for stocks that have significantly outperformed for several months to take a breather.

Other stocks mentioned: ALLO, DKNG, MYOK, PLUG, UTHR, YY
8 months ago - Kiplinger

Acceleron Pharma's (XLRN) CEO Habib Dable on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Acceleron (XLRN) posts a narrower-than-expected Q2 loss owing to increased revenues.

9 months ago - Zacks Investment Research

Acceleron (XLRN) delivered earnings and revenue surprises of 38.18% and 23.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

9 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

9 months ago - Business Wire

About XLRN

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candida... [Read more...]

Industry
Biotechnology
IPO Date
Sep 19, 2013
CEO
Habib Dable
Employees
312
Stock Exchange
NASDAQ
Ticker Symbol
XLRN
Full Company Profile

Financial Performance

In 2020, XLRN's revenue was $92.52 million, an increase of 25.04% compared to the previous year's $73.99 million. Losses were -$166.03 million, 33.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for XLRN stock is "Buy." The 12-month stock price forecast is 153.69, which is an increase of 31.92% from the latest price.

Price Target
$153.69
(31.92% upside)
Analyst Consensus: Buy